These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18664477)

  • 1. Fibrillatory rate response to candesartan in persistent atrial fibrillation.
    Bollmann A; Tveit A; Husser D; Stridh M; Sörnmo L; Smith P; Olsson SB
    Europace; 2008 Oct; 10(10):1138-44. PubMed ID: 18664477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candesartan in the prevention of relapsing atrial fibrillation.
    Tveit A; Grundvold I; Olufsen M; Seljeflot I; Abdelnoor M; Arnesen H; Smith P
    Int J Cardiol; 2007 Aug; 120(1):85-91. PubMed ID: 17113170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atrial fibrillatory rate and risk of stroke in atrial fibrillation.
    Bollmann A; Husser D; Lindgren A; Stridh M; Härdig BM; Piorkowski C; Arya A; Sörnmo L; Olsson SB
    Europace; 2009 May; 11(5):582-6. PubMed ID: 19287016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of angiotensin receptor blockade on serial P-wave signal-averaged electrocardiograms after electrical cardioversion of persistent atrial fibrillation.
    Hegbom F; Tveit A; Grundvold I; Arnesen H; Smith P
    Europace; 2009 Oct; 11(10):1301-7. PubMed ID: 19666643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrocardiographic characteristics of fibrillatory waves in new-onset atrial fibrillation.
    Husser D; Cannom DS; Bhandari AK; Stridh M; Sörnmo L; Olsson SB; Bollmann A
    Europace; 2007 Aug; 9(8):638-42. PubMed ID: 17470676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exercise testing for non-invasive assessment of atrial electrophysiological properties in patients with persistent atrial fibrillation.
    Husser O; Husser D; Stridh M; Sörnmo L; Corino VD; Mainardi LT; Lombardi F; Klein HU; Olsson SB; Bollmann A
    Europace; 2007 Aug; 9(8):627-32. PubMed ID: 17595231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrial fibrillatory rate and risk of left atrial thrombus in atrial fibrillation.
    Bollmann A; Husser D; Stridh M; Holmqvist F; Roijer A; Meurling CJ; Sörnmo L; Olsson SB
    Europace; 2007 Aug; 9(8):621-6. PubMed ID: 17604306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II blockade, YKL-40 and maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation.
    Tveit A; Seljeflot I; Smith P; Arnesen H; Svendsen JH
    Immunobiology; 2013 Oct; 218(10):1256-60. PubMed ID: 23731775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-arginine, asymmetric dimethylarginine and rhythm outcome after electrical cardioversion for atrial fibrillation.
    Tveit A; Arnesen H; Smith P; Bratseth V; Seljeflot I
    Cardiology; 2010; 117(3):176-80. PubMed ID: 21063118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation and clinical application of time-frequency analysis of atrial fibrillation electrocardiograms.
    Husser D; Stridh M; Cannom DS; Bhandari AK; Girsky MJ; Kang S; Sörnmo L; Bertil Olsson S; Bollmann A
    J Cardiovasc Electrophysiol; 2007 Jan; 18(1):41-6. PubMed ID: 17229299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atrial fibrillatory rate and sinus rhythm maintenance in patients undergoing cardioversion of persistent atrial fibrillation.
    Holmqvist F; Stridh M; Waktare JE; Sörnmo L; Olsson SB; Meurling CJ
    Eur Heart J; 2006 Sep; 27(18):2201-7. PubMed ID: 16956916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation.
    Tveit A; Seljeflot I; Grundvold I; Abdelnoor M; Smith P; Arnesen H
    Am J Cardiol; 2007 Jun; 99(11):1544-8. PubMed ID: 17531578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candesartan, NT-proBNP and recurrence of atrial fibrillation after electrical cardioversion.
    Tveit A; Seljeflot I; Grundvold I; Abdelnoor M; Arnesen H; Smith P
    Int J Cardiol; 2009 Jan; 131(2):234-9. PubMed ID: 18201783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.
    Goette A; Schön N; Kirchhof P; Breithardt G; Fetsch T; Häusler KG; Klein HU; Steinbeck G; Wegscheider K; Meinertz T
    Circ Arrhythm Electrophysiol; 2012 Feb; 5(1):43-51. PubMed ID: 22157519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial.
    Disertori M; Lombardi F; Barlera S; Maggioni AP; Favero C; Franzosi MG; Lucci D; Staszewsky L; Fabbri G; Quintarelli S; Bianconi L; Latini R
    Am Heart J; 2011 Aug; 162(2):382-9. PubMed ID: 21835301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid slowing of the atrial fibrillatory rate after administration of AZD7009 predicts conversion of atrial fibrillation.
    Aunes M; Egstrup K; Frison L; Berggren A; Stridh M; Sörnmo L; Edvardsson N
    J Electrocardiol; 2014; 47(3):316-23. PubMed ID: 24508473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of flecainide on atrial fibrillatory rate in a large animal model with induced atrial fibrillation.
    Hesselkilde EZ; Carstensen H; Haugaard MM; Carlson J; Pehrson S; Jespersen T; Buhl R; Platonov PG
    BMC Cardiovasc Disord; 2017 Dec; 17(1):289. PubMed ID: 29221440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
    Yamashita T; Inoue H; Okumura K; Kodama I; Aizawa Y; Atarashi H; Ohe T; Ohtsu H; Kato T; Kamakura S; Kumagai K; Kurachi Y; Koretsune Y; Saikawa T; Sakurai M; Sato T; Sugi K; Nakaya H; Hirai M; Hirayama A; Fukatani M; Mitamura H; Yamazaki T; Watanabe E; Ogawa S;
    Europace; 2011 Apr; 13(4):473-9. PubMed ID: 21148662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency measures obtained from the surface electrocardiogram in atrial fibrillation research and clinical decision-making.
    Bollmann A; Husser D; Stridh M; Soernmo L; Majic M; Klein HU; Olsson SB
    J Cardiovasc Electrophysiol; 2003 Oct; 14(10 Suppl):S154-61. PubMed ID: 14760918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candesartan decreases type III procollagen-N-peptide levels and inflammatory marker levels and maintains sinus rhythm in patients with atrial fibrillation.
    Kawamura M; Ito H; Onuki T; Miyoshi F; Watanabe N; Asano T; Tanno K; Kobayashi Y
    J Cardiovasc Pharmacol; 2010 May; 55(5):511-7. PubMed ID: 20164787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.